Tuesday, November 11, 2025 | 11:02 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Eris Lifesciences Q3 net up 42% to Rs 90 cr, total income rises by 14%

Overall, the company saw decent growth in its product segments, led by cardio metabolic and vitamin-mineral-nutrients

Eris Lifesciences
premium

While cardio metabolic saw a 13.6 per cent, VMN saw a 39.3 per cent growth in Q3 of FY'21 for Eris Lifesciences.

Vinay Umarji Ahmedabad
Ahmedabad-based drug maker Eris Lifesciences Ltd. has posted a 42 per cent rise in its consolidated net profit for the third quarter of financial year 2020-21 at Rs 90.1 crore. Last year the company registered a consolidated Q3 net profit of Rs 63.4 crore.

The company's consolidated total income grew by 14 per cent to Rs 313.4 crore in the said quarter, as compared to Rs 274.8 crore in Q3 the previous fiscal. 

Overall, the company saw decent growth in its product segments, led by cardio metabolic and vitamin-mineral-nutrients (VMN). Excluding Covid molecules, the company saw a year-on-year (YoY) growth